Unichem plans sale of domestic formulations business; valuation seen at $1-1.2 billion

Unichem plans sale of domestic formulations business; valuation seen at $1-1.2 billion

Medium-sized Indian drugmaker Unichem LabsBSE -0.31 % is exploring the sale of its domestic formulations business. The proposal by one of India’s oldest pharmaceutical companies is at a preliminary stage and is being studied by large strategic investors and private equity firms, several people told ET.Investment bank Jefferies has been hired to seek potential suitors. The valuation could be $1-1.2 billion, said one of those cited above.
Read more at:
http://economictimes.indiatimes.com/articleshow/49315531.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

#Indian #Pharma #Market (IPM) Major Highlights for #September #2015

Indian Pharma market Highlights-Sept-2015

Indian Pharma Market (IPM) Major Highlights for September 2015Sep-15 witnessed a growth of 9.90% for the month. The average Growth of IPM since April has been 13.4%. Anti-Infective and Respiratory Market have pulled the growths down. With Sep – 15 we have closed the 2nd Quarter and the 1st half of fiscal 15-16

September- 15 also witnessed addition of 774 Crs over August-15 which is the lowest since April -15. However the point that also to be noted that Sep 14 was on a high base by adding up 1286 Crs over Sep -13 with a growth of 19.6%

…………………………………………………………………………………….

Companies:

Among the top 10, Zydus* grew by 12.6% followed by Lupin at 12.4% & Sun* at 11.8%
………………………………………………………………………………..
20 corporate have crossed the growth of IPM for the month of September 2015 among top 50
…………………………………………………………………………………………
Among the top 50 Corporate, Wockhardt has the highest growth of 42.3% followed by Troikaa at 38.2% & AstraZeneca at 37.8 %
……………………………………………………………………………….
18 Cos showed growth more than 10% among the top 50
……………………………………………………………………………………..
Among the 11-20 ranked Corporate Intas has the highest growth of 27.4% followed by Micro* at 16.7% & Torrent at 16.0%
……………………………………………………………………………………..
Among the 21-30 ranked Cos, Wockhardt has the highest growth at 42.3% followed by MSD* 33.1% & Novartis at 9.7%
………………………………………………………………………………….
Among the 31-40 ranked Corporate, AstraZeneca has the highest growth at 37.8% followed by Bharat Serums at 19.1% & Wallace* at 19.0%
…………………………………………………………………………………………….
Among the 41-50 ranked Corporate, Troikaa has the highest growth at 38.2% followed by Fourrts at 9.9% & Allergan at 5.5%
…………………………………………………………………………………….
Among the 51-60 ranked Corporate, Boehringer grew at 43.4% followed by Corona at 21.5% & Hegde & Hegde at 19.5%
……………………………………………………………………………….
Among the 61-70 ranked Corporate, Fresenius Kabi grew at 63.7% followed by RPG by 19.4% followed by TTK at 16.3%
……………………………………………………………………………………
Troikka becomes the 50th biggest co on MAT Basis and Wallace 40th biggest co in IPM
……………………………………………………………………………….

DPCO, Non DPCO & Non-Scheduled Para 19 Market:

The DPCO containing molecules market grew at 2.8% whereas the non DPCO market grew by 10.9% & Non -Sch Para 19 Market at 11.5% resulting in an overall growth of 9.9% for September 2015
………………………………………………………………………………..
NLEM & Non – NLEM Category showed unit growth at 1.2% and 1.1% respectively. The Non-Sch Para 19 Market grew at 9.0% from unit perspective
………………………………………………………………………………..
Therapy:
From therapy perspective 12 therapies have outgrown the IPM growth
………………………………………………………………………………..
Gynecological Market grew at 13.4%, Respiratory Market grew at 4.1%, Gastrointestinal market grew at 12.8% , Pain & Analgesics market grew at 9.0% whereas Anti-infectives grew at 3.2%
……………………………………………………………………..
Anti-diabetic market grows at 18.1% & Cardiac at 11.8% in Chronic Business
………………………………………………………………………………..
Derma market grew by 12.9% & Urology Market at 12.1%
…………………………………………………………………………….
Regional Dynamics:
From regional perspective 13 regions have outgrown the IPM growth
………………………………………………………………………………..
UP East market grew the highest at 20.7% followed by Haryana market at 20.6% & Uttarakhand + UP West Market at 18.7%
………………………………………………………………
4 regions had negative growth in September 2015
……………………………………………………..
Molecules:
Amoxycillin + Clavulanic Acid Market grew at 0.6% whereas Glimepiride + Metformin grows at 11.3% at No 2.
…………………………………………………………………………………
The markets of Paracetamol grew at 20.3%, Atorvastatin 2.9%, Probiotic Microbes at 19.7%, Cefixime -3.6%, Pantoprazole 7.5%, Montelukast + Levocetrizine at 5.5%, Glimepiride + Metformin + Pioglitazone at 13.7%, Vitamin-D at 22.3%, Hydroquinone + Mometasone + Tretinoin at 12.3%, Voglibose + Metformin + Glimepiride at 42.9%, Rosuvastatin at 22.0%, Protein Supplements at -2.6%, Azithromycin at -7.0%, Calcium Carbonate + Vit D3 market at 18.1%
…………………………………………………………………………………..
Carica Papaya Market became 6 Crs on MAT Basis
………………………………………………………………………………………
Brands:
Monocef leads the pack with 34 Crs followed by Mixtard, Spasmoproxyvon Plus, Augmentin and Corex for September 15

Spasmoproxyvon Plus grew at 127.3% followed by Janumet at 104%, Corex 44% Among top 10 Brands

Few Brands who have gained ranks include Rotarix (+133), Mifegest Kit (+110), Meronem (+86), Chymoral Forte (+73), Omez (+50), Trajenta (+44), Betnovate C (+41), Vertin (+40), Janumet (+39), Rantac (+32), Panderm Plus, Istamet (+31), Betnesol (+29), levipil (+28), Spasmoproxyvon Plus (+25), Rosuvas (+24), Shelcal (+16), Dolo (+12), Orofer XT (+11), Among top 100 Brands over September -14
………………………………………………………………………………………..
Caripill moves into Top 500 Brands for the month of Sep -15
…………………………………………………………………………..
300th Biggest Brand is Gestofit from Alembic
………………………………………………………………………………….
New Launches in IPM:

Total 253 Brands & 437 SKUs launched in September 2015

Top New Brands for September -15 are Vilazine, Lupiheme & Vilano

Biggest New Launch by an MNC are Amicolon SB, Stugeron Plus & BHRF in September 2015

Source: AIOCD Pharmasofttech AWACS